Zoledronic Acid in Genitourinary Cancer

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2013 Apr 26

PMID 23615978

Citations 1

Authors

M A Climent

U Anido

M J Mendez-Vidal

J Puente

Affiliations

Soon will be listed here.

Abstract

Bone metastases are a common complication of advanced prostate cancer and while they are less common in non-prostate genitourinary (GU) malignances, they have been reported in up to 35 % of patients with advanced renal cell carcinoma and bladder cancer. Furthermore, they may occur in more than two-thirds of those patients with bladder cancer who develop distant metastases. In the absence of bone-targeted therapies, approximately 50 % of all patients with metastatic bone disease from GU cancers experience at least one skeletal-related event within their lifetime. Zoledronic acid is a bisphosphonate that has been shown to delay or prevent the development of skeletal complications in patients with bone metastases and reduce bone pain in these patients. Furthermore, zoledronic acid has also demonstrated the ability to prevent osteopenia, which may occur with the prolonged use of some pharmacological interventions in patients with cancer.

Citing Articles

An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol.

Tada Y, Hiroshima K, Shimada H, Shingyoji M, Suzuki T, Umezawa H Springerplus. 2016; 5:195.

PMID: 27026891 PMC: 4769234. DOI: 10.1186/s40064-016-1893-2.

References

Saad F, Gleason D, Murray R, Tchekmedyian S, Venner P, Lacombe L . A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94(19):1458-68. DOI: 10.1093/jnci/94.19.1458. View

Ryan C, Huo D, Demers L, Beer T, Lacerna L . Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol. 2006; 176(3):972-8. DOI: 10.1016/j.juro.2006.04.078. View

Motzer R, Basch E . Targeted drugs for metastatic renal cell carcinoma. Lancet. 2007; 370(9605):2071-3. DOI: 10.1016/S0140-6736(07)61874-1. View

Benderson D, Karakunnel J, Kathuria S, Badros A . Scleritis complicating zoledronic acid infusion. Clin Lymphoma Myeloma. 2006; 7(2):145-7. DOI: 10.3816/CLM.2006.n.053. View

Strang P, Nilsson S, Brandstedt S, Sehlin J, Borghede G, Varenhorst E . The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anticancer Res. 1998; 17(6D):4717-21. View

Kilickap S, Ozdamar Y, Altundag M, Dizdar O . A case report: zoledronic acid-induced anterior uveitis. Med Oncol. 2008; 25(2):238-40. DOI: 10.1007/s12032-007-9006-2. View

Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A . Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer. 2012; 107(10):1665-71. PMC: 3493858. DOI: 10.1038/bjc.2012.385. View

Saad F, Lipton A, Cook R, Chen Y, Smith M, Coleman R . Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007; 110(8):1860-7. DOI: 10.1002/cncr.22991. View

Smith M, Eastham J, Gleason D, Shasha D, Tchekmedyian S, Zinner N . Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003; 169(6):2008-12. DOI: 10.1097/01.ju.0000063820.94994.95. View

10.

Kinnane N . Burden of bone disease. Eur J Oncol Nurs. 2007; 11 Suppl 2:S28-31. DOI: 10.1016/j.ejon.2007.07.002. View

11.

Smith Jr J . Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J Urol. 1989; 141(1):85-7. DOI: 10.1016/s0022-5347(17)40597-0. View

12.

Patil S, Figlin R, Hutson T, Michaelson M, Negrier S, Kim S . Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2010; 22(2):295-300. DOI: 10.1093/annonc/mdq342. View

13.

Marx R, Cillo Jr J, Ulloa J . Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007; 65(12):2397-410. DOI: 10.1016/j.joms.2007.08.003. View

14.

Ferlay J, Parkin D, Steliarova-Foucher E . Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010; 46(4):765-81. DOI: 10.1016/j.ejca.2009.12.014. View

15.

Mullin E, Glenn J, Paulson D . Lesions of bone and bladder cancer. J Urol. 1975; 113(1):45-6. DOI: 10.1016/s0022-5347(17)59403-3. View

16.

Epstein M, Wicknick F, Epstein J, Berenson J, Gorsky M . Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010; 110(5):593-6. DOI: 10.1016/j.tripleo.2010.05.067. View

17.

Tirelli G, Biasotto M, Chiandussi S, Dore F, De Nardi E, Di Lenarda R . Bisphosphonate-associated osteonecrosis of the jaws: the limits of a conservative approach. Head Neck. 2009; 31(9):1249-54. DOI: 10.1002/hed.21019. View

18.

Saylor P, Smith M . Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009; 181(5):1998-2006. PMC: 2900631. DOI: 10.1016/j.juro.2009.01.047. View

19.

Michaelson M, Kaufman D, Lee H, McGovern F, Kantoff P, Fallon M . Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007; 25(9):1038-42. PMC: 3047397. DOI: 10.1200/JCO.2006.07.3361. View

20.

Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis C . Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009; 27(32):5356-62. DOI: 10.1200/JCO.2009.21.9584. View